Publication:
A less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: Intravenous diclofenac sodium versus placebo

Simple item page
dc.contributor.affiliationsFaculty of Medicine and Health Sciences
dc.contributor.affiliationsUniversiti Kebangsaan Malaysia (UKM) Medical Centre
dc.contributor.affiliationsUniversiti Sains Islam Malaysia (USIM)
dc.contributor.authorChik I.A.N.en_US
dc.contributor.authorJarmin R.en_US
dc.contributor.authorAriffin A.en_US
dc.contributor.authorOthman H.en_US
dc.contributor.authorZuhdi Z.en_US
dc.contributor.authorAzman A.en_US
dc.contributor.authorMahmood N.R.K.N.en_US
dc.date.accessioned2024-05-28T08:41:35Z
dc.date.available2024-05-28T08:41:35Z
dc.date.issued2018
dc.description.abstractObjective: The purpose of this study is to reduce the incidence of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) by the administration of intravenous (IV) diclofenac sodium. Methods: This is a prospective, randomized, double-blinded control study. This study was performed in the hepatobiliary unit of general surgery department in University Kebangsaan Malaysia Medical Centre (UKMMC) from May 2015 to May 2016. A total of 128 patients were enrolled in this study. 59 patients were randomized into the treatment arm, while 63 were randomized into the control group. Patients were randomized by envelope system, and patients in the treatment arm received 75 mg of diclofenac sodium intravenously, within 30 min of ERCP commencement. Both groups were observed for PEP post-ERCP and their pain score recorded. Patients' demographic data were also observed. Results: A total of 122 patients were included in the study, with 59 patients randomized into the treatment arm and 63 into the placebo arm. There was an increase of 7.6% PEP rates in the placebo group (12.7% vs. 5.1% in the treatment arm). However, this was not statistically significant (p=0.142) Conclusion: This study shows that IV diclofenac sodium can decrease PEP but is not statistically significant.en_US
dc.description.natureFinalen_US
dc.identifier.doi10.22159/ajpcr.2018.v11i10.26474
dc.identifier.epage144
dc.identifier.issn9742441
dc.identifier.issue10
dc.identifier.scopus2-s2.0-85054595577
dc.identifier.spage140
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85054595577&doi=10.22159%2fajpcr.2018.v11i10.26474&partnerID=40&md5=92a9f38af2c4597396522d21b037ed69
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/9300
dc.identifier.volume11
dc.languageEnglish
dc.language.isoen_USen_US
dc.publisherInnovare Academics Sciences Pvt. Ltden_US
dc.relation.ispartofOpen Accessen_US
dc.relation.ispartofAsian Journal of Pharmaceutical and Clinical Research
dc.sourceScopus
dc.subjectAnti-inflammatory agentsen_US
dc.subjectCholangiopancreatographyen_US
dc.subjectEndoscopic retrogradeen_US
dc.subjectNonsteroidalen_US
dc.subjectPainen_US
dc.subjectProspective studiesen_US
dc.titleA less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis: Intravenous diclofenac sodium versus placeboen_US
dc.title.alternativeAsian J. Pharm. Clin. Res.en_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
A less invasive method of reducing the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis Intravenous diclofenac sodium versus placebo.pdf
Size:
815.2 KB
Format:
Adobe Portable Document Format
Download

Collections

Scopus